CCL26 and polyp: Dupilumab reduced tissue ECP, pulmonary and activation-regulated chemokine (PARC) and eotaxin-1 significantly compared with placebo in polyp tissue, total IgE and Eotaxin-3 in nasal secretions, and plasma eotaxin-3, serum total IgE and eosinophils in the circulation.15, 17 This demonstrated that dupilumab targets a spectrum of type-2 inflammatory markers at organ and systemic levels (Table 3).